ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177
31. Juli 2023 09:00 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, Germany and Indianapolis, IN, USA, July 31, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and POINT Biopharma Global Inc. (NASDAQ:...
ITM to Host Theranostics Symposium on Clinical Need and Supply at SNMMI Annual Meeting on Sunday, June 25, 2023
15. Juni 2023 04:23 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, June 15, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will host a multidisciplinary symposium titled,...
ITM eröffnet weltweit größte Anlage zur Produktion von Lutetium-177 für zielgerichtete Radionuklidtherapien gegen Krebs
13. Juni 2023 02:00 ET
|
ITM Isotope Technologies Munich SE
Neue Herstellungsanlage in Neufahrn bei München verzehnfacht ITMs Produktionskapazitäten Feierliche Eröffnung durch Staatsminister Dr. Florian Herrmann, Leiter der Bayerischen Staatskanzlei ...
ITM Opens World's Largest Lutetium-177 Production Facility for Targeted Radionuclide Therapies Against Cancer
13. Juni 2023 02:00 ET
|
ITM Isotope Technologies Munich SE
New manufacturing plant in Neufahrn near Munich increases ITM's production capacity tenfoldCeremonial opening by Minister of State, Dr. Florian Herrmann, Head of the Bavarian State Chancellery ...
ITM Announces €255m Investment Round, Plans to Advance Radiopharmaceutical Pipeline and to Expand Radioisotope Production Capacities
05. Juni 2023 05:00 ET
|
ITM Isotope Technologies Munich SE
One of the largest private investment rounds in European biotech to-dateNet proceeds will enhance ITM’s radiopharmaceutical pipeline, bolster commercial infrastructure, expand leading...
ITM Enters Cooperation Agreement with Paul Scherrer Institute (PSI) for Co-Development and Upscaled Manufacturing of Terbium-161 for Theranostic Application in Cancer
27. April 2023 05:00 ET
|
ITM Isotope Technologies Munich SE
Enhancement of ITM’s development and manufacturing activities strengthens ITM’s position as a pioneer and leader in Targeted Radionuclide Therapy (TRT) Garching / Munich, April 27, 2023 – ITM...
ITM Appoints Roger Estafanos as U.S. General Manager and Expands Presence with Opening of U.S. Headquarters in Princeton, New Jersey
17. April 2023 08:03 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich and Princeton, NJ, April 17, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical theranostics company, today announced that the company has opened its U.S....
ITM lädt zu Symposium und Messestand auf der Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin in Leipzig ein
14. April 2023 05:48 ET
|
ITM Isotope Technologies Munich SE
Garching / München, 14. April 2023 – ITM Isotope Technologies Munich SE (ITM), ein führendes radiopharmazeutisches Biotech-Unternehmen, nimmt an der 61. Jahrestagung der Deutschen Gesellschaft für...
ITM to Present Phase III COMPOSE Poster and Host Satellite Symposium on Radiotheranostics in NET cancer at ENETS Conference
16. März 2023 09:48 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, March 16, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical theranostics company, today announced that the company will present an overview of genetic...
ITM, Helmholtz Munich and University Hospital Münster Announce Start of Phase I Clinical Trial with Radiotherapeutic ITM-31 for Glioblastoma
13. März 2023 06:13 ET
|
ITM Isotope Technologies Munich SE
Garching/Munich, Munich and Münster, Germany, March 13, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, Helmholtz Munich and the Departments of...